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Abstract
Background:  Pulmonary giant cell carcinoma is one of the rare histological subtypes with
pleomorphic, sarcomatoid or sarcomatous elements. The prognosis of patients with this tumor
tends to be poor, because surgery, irradiation and chemotherapy are not usually effective.
Case presentation: We herein report a patient with pulmonary giant cell carcinoma with stage
IV disease in whom aggressive multi-modality therapy resulted in a long-term survival. A 51-year-
old male underwent an emergent operation with a partial resection of small intestinal metastases
due to bleeding from the tumor. The patient also underwent a left pneumonectomy due to
hemothorax as a result of the rapid growth of the primary tumor. Thereafter, two different
regimens of chemotherapy and a partial resection for other site of small intestinal metastases and
a splenectomy for splenic metastases were performed. The patient is presently doing well without
any evidence of recurrence for 3 years after the initial operation.
Conclusion: This is a first report of a rare case with stage IV pulmonary giant cell carcinoma who
has survived long-term after undergoing aggressive surgical treatment and chemotherapy.
Background
The recent World Health Organization (WHO) classifica-
tion of lung tumors has unified the heterogeneous group
of non-small cell lung carcinomas that contains sarcoma
or sarcoma-like components under the designation of
"carcinomas with pleomorphic, sarcomatoid or sarcoma-
tous elements" [1]. This group includes different entities,
such as pleomorphic carcinoma, spindle cell carcinoma,
giant cell carcinoma, carcinosarcoma and pulmonary
blastoma. In general, these tumors are rare, comprising
approximately from 0.1–0.4% of all lung malignancies [2-
4]. The patients with these tumors tend to demonstrate a
despondent clinical course and the prognosis for them is
gernally poor [5], because surgery, irradiation and chem-
otherapy are ineffective. We experienced a pulmonary
giant cell carcinoma patient with stage IV disease in whom
aggressive multi-modality therapy consisting of surgical
resections for the primary lesion and multi-organ metas-
tases and also chemotherapy which together resulted in a
long-term survival.
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Case presentation
A 51-year-old male was admitted in June 2001, due to
hemosputum, cough, hemo-stool and an abnormal
shadow on a chest roentgenogram. Laboratory results
showed severe anemia with hemoglobin of 4.0 g/dl (13.6
< normal range < 16.8 g/dl) and hematocrit of 16.0 % (40
< normal range < 48 %). The patient's chest X-ray demon-
strated a huge mass lesion in the left upper lung field (Fig-
ure 1). Computed tomography (CT) of the chest showed
a mass shadow, measuring 7.0 × 7.0 cm in size in the left
upper lobe (S1+2) without any invasion of the surround-
ing tissue such as the vessels, plexus or thoracic wall and
with no mediastinal lymph node swelling. Abdominal CT
revealed a huge mass, measuring 12.7 × 7.5 cm in size in
the small intestine. Prior to performing any treatment for
the presumed lung cancer, we tried to stop the continuous
bleeding from tumor in the small intestine. As a result, we
performed an emergency operation. The tumor was
observed in the jejunum at a location about 30 cm from
the ligament of Treitz on the anal side and a 25 cm length
of the jejunum, including the tumor, was thus resected.
Six days later, the patient experienced sudden chest pain,
dyspnoea and hemoptysis. The patient's chest X ray
showed the left lung mass shadow to have rapidly
increased in size, while the broncho-fiberscopy findings
showed bleeding from the left upper bronchus and an
obstruction of the left lower bronchus due to coagulation.
Hemothorax due to a rupture of the lung induced by the
rapid growth of the tumor was found after an emergency
thoracotmy. The tumor was so large that it was difficult to
approach the interlobular pulmonary artery. Therefore, a
left pneumonectomy with mediastinal lymph nodal dis-
section was performed. Thereafter, intraoperative intrap-
leural hypotonic cisplatin treatment [6] was performed
because some tumor cells were suspected to exist in the
pleural cavity due to the rupture of the tumor. A histolog-
ical examination revealed pure giant cell carcinoma con-
taining no sarcomatoid component, similar to that found
in the small intestine (Figure 2). As a result, we diagnosed
the patient to have stage IV disease (pathological stage
T2N0M1) according to the TNM classification [1]. The
patient had an uneventful recovery without any complica-
tions. However, about 4 months after the first operation,
the patient was diagnosed to have a recurrence at another
site in the small intestine and spleen by abdominal CT.
The patient received 2 cycles of chemotherapy (cisplatin
40 mg/m2 + gemcitabine 800 mg/m2+ vinorelbine 20 mg/
m2), at days 1 and 8, and thereafter every 4 weeks). The
splenic metastases increased in size while the size of the
tumor in the small intestine decreased. At this time, no
recurrence site except for those in the small intestine and
spleen were found, therefore, to avoid the risk of bleeding
either from tumors in the small intestine or a rupture of
spleen in the future, surgical treatment consisting of a par-
tial resection of the small intestine and a splenectomy was
performed. The intestinal tumor was found in the jeju-
num at a location about 10 cm from the ligament of Treitz
on the anal side and a total 20 cm length of the jejunum,
including the tumor, was resected. A pathological exami-
nation revealed a proliferation of pure giant cell carci-
noma with extensive necrosis both in the small intestine
and the spleen, thus suggesting the chemotherapy to be
effective in the both organs. Thereafter, the patient
received 2 additional cycles of this triplet chemotherapy.
The patient experienced neither any hematological nor
severe non-hematological adverse events. About 6
months later, metastases in multiple abdominal lymph
nodes were found (Figure 3A). The patient was started on
chemotherapy (carboplatin AUC = 2 + paclitaxel 60 mg/
m2, on days 1 and 8, and thereafter every 3 weeks). After
receiving a total of 10 cycles of chemotherapy on an out-
patient basis, abdominal CT showed the chemotherapeu-
tic effect to be a complete response (Figure 3B), without
any severe hematological or non-hematological adverse
events. At present, the patient has survived for about 3-
years since the first operation and a complete response has
been maintained for 15 months.
Discussion
According to the treatment guidelines for unresectable
non-small cell lung cancer of American Society of Clinical
Oncology (ASCO)[7], chemotherapy prolongs survival
and is the most appropriate treatment for stage IV patients
with a good performance status. Although both resections
of primary lung cancer and either brain or adrenal
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metastases are occasionally recommended in highly
selected patients, a surgical resection of other metasta-
sized sites is hardly ever performed. Therefore, the present
patient is an extremely rare case because he underwent an
emergency surgical resection of small intestinal metas-
tases and a primary tumor due to bleeding from both
tumors, as well as a surgical resection of other metastases
in the small intestine and spleen in order to avoid a risk of
bleeding from the recurrent site in the future.
Fishback et al, reported the overall survival of total 78
patients with pleomorphic (spindle/ giant cell) carcinoma
(stage I-IV), among whom 57 patients received a surgical
resection, to be poor with a median survival time of 10
months and a survival rate of 10% at 5 years [8]. Accord-
ing to Chang et al, the mean survival time of resected ple-
omorphic carcinoma patients was 5 months while the
median survival time of pleomorphic carcinoma patients
treated with concurrent or sequential chemo-radiotherapy
was 2.7 months [9]. To our knowledge, a case of a long-
term survivor with stage IV pleomorphic (spindle/ giant
cell) carcinoma has never been previously reported. The
tumor histology of the present case was very rare, pure
giant cell carcinoma, which belongs to the category of car-
cinomas with pleomorphic, sarcomatoid or sarcomatous
elements according to new WHO classification, and the
prognosis is estimated to be poor. Although pleomorphic
carcinoma has been reported to usually be resistant to
chemotherapy, we first chose chemotherapy including cis-
platin, gemcitabine and vinorelbine, which has been
shown to demonstrate the highest response rate in
advanced non-small cell lung cancer based on our experi-
ence. In our prior phase II trial using this combination
chemotherapy in 79 advanced non-small cell lung cancer
patients, the response rate was 56% and the 1-year sur-
vival rate was 75% while the toxicity levels were accepta-
ble [10]. After recurrence, we chose chemotherapy with
carboplatin and paclitaxel, which is most frequently used
for the treatment of advanced non-small cell lung cancer.
Since the standard treatment method using carboplatin
and paclitaxel in Japan is the administration of AUC of 6
and 200 mg/m2, respectively once every 3 weeks [11], the
administered regimen (carboplatin AUC = 2 and paclit-
axel 60 mg/m2, on days 1 and 8, and thereafter every 3
weeks) in this patient was unusual and the dose intensity
was relatively small. However, this regimen nevertheless
effectively treated his disease and he was also able to work
normally during the treatment process. At present, the
patient has survived for 3 years since the first operation
and has remained healthy without any signs of recurrence
for 15 months after the last treatment.
Conclusion
This is a first report of a rare case with stage IV pulmonary
giant cell carcinoma who has survived long-term after
undergoing aggressive surgical treatment and
chemotherapy.
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Pathological findings of the left lung Figure 2
Pathological findings of the left lung. The section consists of a 
diffuse proliferation of atypical, giant and bizarre cells (arrow-
head). No sarcomatoid component is seen.
Computerised tomographic scan before and after treatment Figure 3
Computerised tomographic scan before and after treatment. 
A) Abdominal CT showed multiple lymph node swelling, sug-
gesting the presence of metastases (arrowhead). B) Abdomi-
nal CT showed the lymph nodes metastases to have 
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